A Randomized Ph 3 Study Comparing First-Line Pemetrexed/Cisplatin Followed by Gefitinib With Gefitinib Alone in East Asian Never Smoker or Light Ex-Smoker Patients With Locally Advanced or Metastatic Nonsquamous NSCLC
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2016
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary) ; Gefitinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 02 Jun 2015 Results of final analysis presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 10 Dec 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 15 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.